Abcodia is a clinical stage company engaged in the development of novel tests for the early detection of cancer. The Company’s first product is the ROCA® Test for the early detection of ovarian cancer.
Abcodia’s products are based on expertise in measuring and modelling dynamic changes over time of clinical variables including test results from serum-based markers before cancer is clinically diagnosed.
Abcodia is a privately held company funded through investments from Albion Ventures, Cambridge Innovation Capital, Scottish Equity Partners and UCL Business. The company is headquartered in U.K.